Chimeric Antigen Receptor T Cells in Multiple Myeloma

Parth Shah; Adam S Sperling

doi:10.1016/j.hoc.2023.05.008

Chimeric Antigen Receptor T Cells in Multiple Myeloma

Hematol Oncol Clin North Am. 2023 Dec;37(6):1089-1105. doi: 10.1016/j.hoc.2023.05.008. Epub 2023 Aug 8.

Authors

Parth Shah¹, Adam S Sperling²

Affiliations

¹ Department of Hematology, Dartmouth Cancer Center, 1 Medical Center Drive, Lebanon, NH 03750, USA; Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: Parth_Shah@DFCI.HARVARD.EDU.
² Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA; Division of Hematology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

PMID: 37563077
DOI: 10.1016/j.hoc.2023.05.008

Abstract

Multiple myeloma is the second most common hematological malignancy with an approximate incidence of up to 8.5 cases per 100,000 persons per year. Over the last decade, therapy for multiple myeloma has undergone a revolutionary change. Chimeric antigen receptor (CAR) T-cell therapy has played a major role in this evolution. In this review, we discuss the existing state of CAR T-cell therapy in myeloma while evaluating several newer therapies and targets expected in the near future.

Keywords: BCMA; BiTEs; CAR-T; GPRC5D; Multiple myeloma.

Publication types

Review

MeSH terms

B-Cell Maturation Antigen
Humans
Immunotherapy, Adoptive
Multiple Myeloma* / pathology
Multiple Myeloma* / therapy
Receptors, Chimeric Antigen* / genetics
T-Lymphocytes

Substances

Receptors, Chimeric Antigen
B-Cell Maturation Antigen

Grants and funding

K08 CA252174/CA/NCI NIH HHS/United States